A High Throughput Protein Formulation Platform: Case Study of Salmon Calcitonin

被引:29
作者
Capelle, Martinus A. H. [1 ]
Gurny, Robert [1 ]
Arvinte, Tudor [1 ]
机构
[1] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Dept Pharmaceut & Biopharmaceut, CH-1211 Geneva 4, Switzerland
关键词
high throughput screening; protein formulation; salmon calcitonin; spectroscopy; stability; FLUORESCENT-PROBE; NILE RED; BIOGENERICS;
D O I
10.1007/s11095-008-9662-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The feasibility of using high throughput spectroscopy for characterization and selection of physically stable protein formulations was studied. A hundred aqueous formulations of salmon calcitonin (sCT) were prepared using 20 buffer compositions. The solutions had pH values between 2.5 and 10.5. The stability of the sCT formulations was analyzed over 1 week by the following assays: (1) protein concentration, (2) volume control by measuring pathlength, (3) turbidity (absorbance at 350 nm), (4) intrinsic tyrosine fluorescence, (5) 1-anilino-naphthalene-8-sulfonate (ANS) fluorescence, (6) Nile Red fluorescence. Addition of the dyes (Nile Red and ANS) was used to study protein conformational changes. After 1 day, 27 out of the 100 formulations of salmon calcitonin were stable. After 7 days, 12 stable sCT formulations remained. The best salmon calcitonin formulation was in 10 mM sodium acetate buffer with pH values between 3.5 and 5.5. The findings are in accordance with the sCT formulations that were patented and used commercially. This can be considered as a proof of concept for the high throughput protein formulation platform.
引用
收藏
页码:118 / 128
页数:11
相关论文
共 23 条
[1]   8-anilino-1-naphthalene sulfonic acid (ANS) induces folding of acid unfolded cytochrome c to molten globule state as a result of electrostatic interactions [J].
Ali, V ;
Prakash, K ;
Kulkarni, S ;
Ahmad, A ;
Madhusudan, KP ;
Bhakuni, V .
BIOCHEMISTRY, 1999, 38 (41) :13635-13642
[2]  
ARVINTE T, 1993, J BIOL CHEM, V268, P6415
[3]  
ARVINTE T, 1993, J BIOL CHEM, V268, P6408
[4]   A fluorescence-based high-throughput assay for antimicrotubule drugs [J].
Barron, DM ;
Chatterjee, SK ;
Ravindra, R ;
Roof, R ;
Baloglu, E ;
Kingston, DGI ;
Bane, S .
ANALYTICAL BIOCHEMISTRY, 2003, 315 (01) :49-56
[5]   Biogenerics at the crossroads [J].
Ben-Maimon, CS ;
Garnick, R .
NATURE BIOTECHNOLOGY, 2006, 24 (03) :268-269
[6]  
Berg M, 2001, J BIOMOL SCREEN, V6, P47, DOI 10.1089/108705701750067024
[7]   High throughput screening of protein formulation stability: Practical considerations [J].
Capelle, Martinus A. H. ;
Gurny, Robert ;
Arvinte, Tudor .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (02) :131-148
[8]   SuperGenerics: a better alternative for biogenerics [J].
Charles, SA .
DRUG DISCOVERY TODAY, 2005, 10 (08) :533-535
[9]   ENHANCED POTENCY OF HUMAN CALCITONIN WHEN FIBRILLATION IS AVOIDED [J].
CUDD, A ;
ARVINTE, T ;
DAS, REG ;
CHINNI, C ;
MACINTYRE, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (06) :717-719
[10]   Detection and characterization of protein aggregates by fluorescence microscopy [J].
Demeule, Barthelemy ;
Gurny, Robert ;
Arvinte, Tudor .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 329 (1-2) :37-45